S&P 500   3,321.96 (-1.04%)
DOW   27,733.44 (-0.60%)
QQQ   265.25 (-1.88%)
AAPL   106.88 (-3.14%)
MSFT   198.24 (-2.30%)
FB   252.56 (-0.89%)
GOOGL   1,449.56 (-2.52%)
AMZN   2,938.38 (-2.34%)
NVDA   484.20 (-2.88%)
TSLA   435.29 (+2.80%)
BABA   272.47 (-1.18%)
CGC   16.42 (+0.12%)
GE   6.98 (-0.99%)
MU   50.69 (-0.57%)
AMD   74.56 (-2.60%)
T   29.06 (-0.03%)
F   7.27 (-0.14%)
ACB   6.60 (-4.21%)
GILD   64.62 (-0.65%)
NFLX   464.12 (-1.29%)
DIS   129.37 (-0.65%)
BAC   25.48 (+0.51%)
BA   163.36 (-2.49%)
S&P 500   3,321.96 (-1.04%)
DOW   27,733.44 (-0.60%)
QQQ   265.25 (-1.88%)
AAPL   106.88 (-3.14%)
MSFT   198.24 (-2.30%)
FB   252.56 (-0.89%)
GOOGL   1,449.56 (-2.52%)
AMZN   2,938.38 (-2.34%)
NVDA   484.20 (-2.88%)
TSLA   435.29 (+2.80%)
BABA   272.47 (-1.18%)
CGC   16.42 (+0.12%)
GE   6.98 (-0.99%)
MU   50.69 (-0.57%)
AMD   74.56 (-2.60%)
T   29.06 (-0.03%)
F   7.27 (-0.14%)
ACB   6.60 (-4.21%)
GILD   64.62 (-0.65%)
NFLX   464.12 (-1.29%)
DIS   129.37 (-0.65%)
BAC   25.48 (+0.51%)
BA   163.36 (-2.49%)
S&P 500   3,321.96 (-1.04%)
DOW   27,733.44 (-0.60%)
QQQ   265.25 (-1.88%)
AAPL   106.88 (-3.14%)
MSFT   198.24 (-2.30%)
FB   252.56 (-0.89%)
GOOGL   1,449.56 (-2.52%)
AMZN   2,938.38 (-2.34%)
NVDA   484.20 (-2.88%)
TSLA   435.29 (+2.80%)
BABA   272.47 (-1.18%)
CGC   16.42 (+0.12%)
GE   6.98 (-0.99%)
MU   50.69 (-0.57%)
AMD   74.56 (-2.60%)
T   29.06 (-0.03%)
F   7.27 (-0.14%)
ACB   6.60 (-4.21%)
GILD   64.62 (-0.65%)
NFLX   464.12 (-1.29%)
DIS   129.37 (-0.65%)
BAC   25.48 (+0.51%)
BA   163.36 (-2.49%)
S&P 500   3,321.96 (-1.04%)
DOW   27,733.44 (-0.60%)
QQQ   265.25 (-1.88%)
AAPL   106.88 (-3.14%)
MSFT   198.24 (-2.30%)
FB   252.56 (-0.89%)
GOOGL   1,449.56 (-2.52%)
AMZN   2,938.38 (-2.34%)
NVDA   484.20 (-2.88%)
TSLA   435.29 (+2.80%)
BABA   272.47 (-1.18%)
CGC   16.42 (+0.12%)
GE   6.98 (-0.99%)
MU   50.69 (-0.57%)
AMD   74.56 (-2.60%)
T   29.06 (-0.03%)
F   7.27 (-0.14%)
ACB   6.60 (-4.21%)
GILD   64.62 (-0.65%)
NFLX   464.12 (-1.29%)
DIS   129.37 (-0.65%)
BAC   25.48 (+0.51%)
BA   163.36 (-2.49%)
Log in
NASDAQ:VBLT

Vascular Biogenics Stock Forecast, Price & News

$1.35
+0.01 (+0.75 %)
(As of 09/18/2020 12:06 PM ET)
Add
Compare
Today's Range
$1.35
Now: $1.35
$1.35
50-Day Range
$1.11
MA: $1.27
$1.40
52-Week Range
$0.90
Now: $1.35
$1.64
Volume1,010 shs
Average Volume457,062 shs
Market Capitalization$56.60 million
P/E RatioN/A
Dividend YieldN/A
Beta0.75
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
Read More
Vascular Biogenics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBLT
Previous SymbolNASDAQ:VBLX
CUSIPN/A
Phone972-8993-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$560,000.00
Book Value$1.00 per share

Profitability

Net Income$-19,460,000.00
Net Margins-2,987.11%

Miscellaneous

Employees38
Market Cap$56.60 million
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$1.35
+0.01 (+0.75 %)
(As of 09/18/2020 12:06 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

How has Vascular Biogenics' stock been impacted by Coronavirus (COVID-19)?

Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VBLT shares have increased by 9.8% and is now trading at $1.34.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Vascular Biogenics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vascular Biogenics
.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Vascular Biogenics
.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd (NASDAQ:VBLT) released its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.14). The biopharmaceutical company earned $0.16 million during the quarter, compared to the consensus estimate of $0.19 million. Vascular Biogenics had a negative return on equity of 57.70% and a negative net margin of 2,987.11%.
View Vascular Biogenics' earnings history
.

What price target have analysts set for VBLT?

4 brokers have issued 12-month price objectives for Vascular Biogenics' stock. Their forecasts range from $2.50 to $5.00. On average, they anticipate Vascular Biogenics' share price to reach $3.88 in the next twelve months. This suggests a possible upside of 189.2% from the stock's current price.
View analysts' price targets for Vascular Biogenics
.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 308,500 shares, a drop of 20.7% from the August 15th total of 389,100 shares. Based on an average daily volume of 353,500 shares, the short-interest ratio is currently 0.9 days. Currently, 1.0% of the shares of the stock are sold short.
View Vascular Biogenics' Short Interest
.

Who are some of Vascular Biogenics' key competitors?

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Opko Health (OPK), Rigel Pharmaceuticals (RIGL), AEterna Zentaris (AEZS), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Heat Biologics (HTBX), Vaxart (VXRT) and Dynavax Technologies (DVAX).

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the following people:
  • Prof. Dror Harats, CEO & Director (Age 63)
  • Mr. Amos Ron, CFO & Company Sec. (Age 65)
  • Dr. Erez Feige, VP of Bus. Operations (Age 46)
  • Dr. Eyal Breitbart, VP of Research & Operations (Age 53)
  • Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 66)

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.11%), Wedbush Securities Inc. (0.05%), Phoenix Holdings Ltd. (0.05%), Virtu Financial LLC (0.05%) and Goldman Sachs Group Inc. (0.05%).

Which major investors are buying Vascular Biogenics stock?

VBLT stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Phoenix Holdings Ltd., Virtu Financial LLC, Goldman Sachs Group Inc., and Envestnet Asset Management Inc..

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.34.

How big of a company is Vascular Biogenics?

Vascular Biogenics has a market capitalization of $56.18 million and generates $560,000.00 in revenue each year. The biopharmaceutical company earns $-19,460,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Vascular Biogenics employs 38 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.